BeOne Medicines (MEX:BGNEN) Beta: 0.0404 (As of Jun. 25, 2026)


MEX:BGNEN BeOne Medicines Ltd MEX:BGNEN
81 GF Score
Price MXN2,858.16
GF Value MXN3,774.03
! 4 Warning Signs
View Full Analysis

What is BeOne Medicines Beta?

BeOne Medicines MEX:BGNEN 81 Beta is 0.0404 as of Jun. 25, 2026. GuruFocus rates MEX:BGNEN with a GF Score™ of 81/100 and a GF Value™ of MXN3,774.03. The stock has 4 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-25), BeOne Medicines's Beta is 0.0404.


BeOne Medicines  (MEX:BGNEN) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


BeOne Medicines Beta Related Terms


BeOne Medicines Beta Historical Data

* Premium members only.

The historical data trend for BeOne Medicines's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BeOne Medicines Beta Chart

BeOne Medicines Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.37 -0.29 0.32 0.36 0.70

BeOne Medicines Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.37 0.47 0.54 0.70 0.02

MEX:BGNEN vs RVMD, RPRX, BNTX: Beta Comparison

For the Biotechnology subindustry, BeOne Medicines's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BeOne Medicines Beta vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BeOne Medicines's Beta distribution charts can be found below:

* The bar in red indicates where BeOne Medicines's Beta falls into.


MEX:BGNEN
81GF Score
BeOne Medicines Ltd MEX:BGNEN
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BeOne Medicines Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 0.0404 mean?
BeOne Medicines (MEX:BGNEN) has a Beta of 0.0404 as of Jun. 25, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for BeOne Medicines and its competitors.
Is BeOne Medicines' Beta too high?
BeOne Medicines' current Beta is 0.0404. Overall, BeOne Medicines has a GF Score™ of 81/100, reflecting its overall financial health beyond just this single metric.
How does BeOne Medicines' Beta compare to RVMD and RPRX?
BeOne Medicines' Beta of 0.0404 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Biotechnology company?
A good Beta depends on the Biotechnology industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for BeOne Medicines and its competitors. BeOne Medicines's current Beta is 0.0404. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BeOne Medicines stock overvalued right now?
BeOne Medicines (MEX:BGNEN) has a current Beta of 0.0404. The stock's GF Value™ is MXN3,774.03, compared to a current price of MXN2,858.16 — trading 24.3% below its estimated fair value. The current Beta is 0.0404. BeOne Medicines' overall GF Score™ is 81/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For BeOne Medicines (MEX:BGNEN), the current Beta is 0.0404 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BeOne Medicines (MEX:BGNEN) Overvalued in 2026?

Based on GuruFocus' analysis, BeOne Medicines stock appears to be undervalued. The current stock price of MXN2,858.16 is trading 24.3% below its estimated GF Value™ of MXN3,774.03.

Key valuation signals for MEX:BGNEN:

  • Beta: 0.0404
  • GF Value™: MXN3,774.03 vs. price of MXN2,858.16 (24.3% below fair value)
  • GF Score™: 81/100 with 4 warning signs

No single metric tells the full story. See the MEX:BGNEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


BeOne Medicines Business Description

Address c/o BeOne Medicines I GmbH, 94 Aeschengraben 27, 21st Floor, Basel, CHE, 4051
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.
81GF Score

Get the complete analysis for MEX:BGNEN

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN2,858.16
Price
MXN3,774.03
GF Value